Professor at NYU and founder of Roubini Macro Associates Nouriel Roubini sits down with PS to discuss Trump and his protectionist policies, Brexit, and further trouble in the EU.
Support High-Quality Commentary
US President-elect Joe Biden may have promised a “return to normalcy,” but the truth is that there is no going back. The world is changing in fundamental ways, and the actions the world takes in the next few years will be critical to lay the groundwork for a sustainable, secure, and prosperous future.
For more than 25 years, Project Syndicate has been guided by a simple credo: All people deserve access to a broad range of views by the world’s foremost leaders and thinkers on the issues, events, and forces shaping their lives. At a time of unprecedented uncertainty, that mission is more important than ever – and we remain committed to fulfilling it.
But there is no doubt that we, like so many other media organizations nowadays, are under growing strain. If you are in a position to support us, please subscribe now.
As a subscriber, you will enjoy unlimited access to our On Point suite of long reads and book reviews, Say More contributor interviews, The Year Ahead magazine, the full PS archive, and much more. You will also directly support our mission of delivering the highest-quality commentary on the world's most pressing issues to as wide an audience as possible.
By helping us to build a truly open world of ideas, every PS subscriber makes a real difference. Thank you.
Although the plight of major US public pension funds is nothing new, the gap between actual and assumed returns is widening faster than ever, owing to today's ultra-low interest rates. But these funds also have inherent advantages that, if used wisely, can place them on a much sounder financial footing.
explains how struggling institutional investors can meet their goals in today's financial environment.
During the pandemic, the UK has led the way in studying pharmaceutical interventions, with well-designed randomized controlled studies enabling vast improvements in patient care globally. Yet, by deciding to increase the gap between vaccine doses, the country's government has effectively abandoned this evidence-based approach.
consider the risks of delaying the second dose of the COVID-19 inoculation.